ORKA-002 clinical trials
Also written ORKA-002.
How each study uses ORKA-002 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ORKA-002 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ORKA-002
- 3
Studies by the year they started
3 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Oruka Therapeutics, Inc. (3)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test ORKA-002.
- Oct 2027Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque PsoriasisPhase 2 · Oruka Therapeutics, Inc.
Studies
Open first, then newest update. How each study uses ORKA-002 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis SuppurativaRecruitingPhase 2Oruka Therapeutics, Inc.NCT07783542Written as ORKA-002
- Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque PsoriasisActive, not recruitingPhase 2Oruka Therapeutics, Inc.NCT07474792Written as ORKA-002
- ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single DoseCompletedPhase 1Oruka Therapeutics, Inc.NCT06944379Written as ORKA-002